July 30 (Reuters) - Scythian Biosciences Corp SCYB.V :
* SCYTHIAN BIOSCIENCES TO ACQUIRE COMPANY WITH EXCLUSIVE MEDICAL CANNABIS LICENSE IN FLORIDA
* SCYTHIAN BIOSCIENCES CORP - WILL INITIALLY PURCHASE 70% OF CANNCURE AND HAVE AN OPTION TO ACQUIRE REMAINING 30%, ALL AT SAME VALUATION
* SCYTHIAN BIOSCIENCES CORP - SIGNED AN ARM'S LENGTH LETTER OF INTENT EFFECTIVE JULY 26, 2018 TO ACQUIRE CANNCURE INVESTMENTS INC
* SCYTHIAN BIOSCIENCES - FIRST 70% TO BE ACQUIRED FOR $93.3 MILLION IN EQUITY AND $43.2 MILLION CASH TO BE INVESTED INTO CANNCURE BY WAY OF DEBT OR EQUITY
* SCYTHIAN BIOSCIENCES CORP - INTENDS TO USE PROCEEDS FROM APHRIA TRANSACTION TO PAY CASH COMPONENT OF ACQUISITION
* SCYTHIAN BIOSCIENCES CORP - EQUITY TO BE PAID IN SCYTHIAN COMMON SHARES, ISSUED TO SHAREHOLDERS OF CANNCURE
* SCYTHIAN BIOSCIENCES CORP - RECEIVED CONDITIONAL APPROVAL TO LIST ITS COMMON SHARES ON CANADIAN SECURITIES EXCHANGE
* SCYTHIAN BIOSCIENCES CORP - INTENDS TO VOLUNTARILY DELIST ITS COMMON SHARES FROM TRADING ON TSX VENTURE EXCHANGE
* SCYTHIAN BIOSCIENCES CORP - HAS ANNOUNCED IT WILL VOLUNTARILY WITHDRAW ITS APPLICATION TO LIST ITS SHARES ON NASDAQ STOCK MARKET LLC